Latest News

Stocks in Play

Dividend Stocks

Breakout Stocks

Tech Insider

Forex Daily Briefing

US Markets

Stocks To Watch

The Week Ahead



Commodity News

Metals & Mining News

Crude Oil News

Crypto News

M & A News


OTC Company News

TSX Company News

Earnings Announcements

Dividend Announcements

Viking Makes its Move

Biotech company Viking Therapeutics (NASDAQ:VKTX) has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market.

Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the end of the decade.

Viking aims to compete with injectable drugs from Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage.

Some Wall Street analysts said Viking’s experimental obesity treatment may be “best-in-class.” In a midstage trial, an injectable version of Viking’s drug appeared to promote even greater weight loss than Eli Lilly’s Zepbound .

Viking gave a first glimpse at data from that study on Tuesday, and its shares soared 120%. The promising results make the company an impressive potential player in a market that will likely have room for more entrants in the coming years.

Goldman Sachs projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. Eli Lilly and Novo Nordisk have also struggled to offer enough supply of their treatments, giving other companies a chance to win market share.

The new data also makes Viking a more attractive deal target for larger companies trying to break into the space or expand their obesity treatment offerings.

VKTX shares leaped to begin Monday and the week by $5.06, or 5.9%, to $90.28.